Search results for "Familial combined hyperlipidemia"

showing 7 items of 7 documents

European Panel on Low Density Lipoprotein (LDL) Subclasses: A Statement on the Pathophysiology, Atherogenicity and Clinical Significance of LDL Subcl…

2011

Item does not contain fulltext Aim of the present Consensus Statement is to provide a comprehensive and up to-date document on the pathophysiology, atherogenicity and clinical significance of low density liproproteins (LDL) subclasses. We sub-divided our statement in 2 sections. section I discusses the pathophysiology, atherogenicity and measurement issues, while section II is focused on the effects of drug and lifestyle modifications. Suggestions for future research in the field are highlighted at the end of section II. Each section includes Conclusions.

cardiovascular riskischemic-heart-diseaseHealth aging / healthy living [IGMD 5]coronary-artery-diseaseapolipoprotein-b metabolismcholesteryl ester transferAtherosclerosisstatementfamilial combined hyperlipidemialdlLipoproteins LDLvery-low-densitynuclear-magnetic-resonancec-reactive proteinRisk FactorsAnimalsHumansGenetic Predisposition to DiseaseLDL subclasses atherosclerosis cardiovascular risk statementsubclassesatherosclerosistype-2 diabetes-mellitusintima-media thickness
researchProduct

“European Panel on Low Density Lipoprotein (LDL) Subclasses”: A Statement on the Pathophysiology, Atherogenicity and Clinical S…

2011

Aim of the present Consensus Statement is to provide a comprehensive and up to-date document on the pathophysiology, atherogenicity and clinical significance of low density lipoproteins (LDL) subclasses. We sub-divided our Statement in 2 sections: section I discusses the pathophysiology, atherogenicity and measurement issues, while section II is focused on the effects of drugs and lifestlyle modifications. Suggestions for future research in the field are highlighted at the end of section II. Each section includes Conclusions.

Pharmacologybusiness.industryStatement (logic)Bioinformaticschemistry.chemical_compoundFamilial combined hyperlipidemiachemistryLow-density lipoproteinImmunologyLow densityMedicineClinical significanceCardiology and Cardiovascular MedicinebusinessCurrent Vascular Pharmacology
researchProduct

Efecto del género y de la obesidad en la lipemia posprandial en sujetos sanos normolipidémicos no diabéticos y sujetos con hiperlipemia familiar comb…

2006

Introduccion Un nuevo metodo basado en la autodeterminacion de trigliceridos (TG) capilares permite un mejor conocimiento de la lipemia posprandial (LP). Los objetivos de nuestro estudio son analizar el efecto del genero y la obesidad sobre la LP valorada por medicion capilar de TG diurnos mediante Accutrend GCT® en sujetos sanos y sujetos con hiperlipemia familiar combinada (HFC). Material y metodos Hemos estudiado a 23 sujetos con HFC no relacionados entre si (10 hombres) y a 45 sujetos (29 hombres) normolipidemicos no diabeticos. Todos ellos realizaron tres perfiles diarios de TG capilares durante una semana. Resultados En los sujetos sanos normolipidemicos no diabeticos encontramos valo…

GynecologyFamilial combined hyperlipidemiamedicine.medical_specialtybusiness.industrySex factorsmedicineGeneral MedicineTriglycerides bloodbusinessCholesterol bloodRevista Clínica Española
researchProduct

TERAPIA CON STATINE IN PAZIENTI SICILIANI AFFETTI DA IPERLIPIDEMIA FAMILIARE COMBINATA

2007

Familial combined hyperlipidemia (FCHL) is the most frequent genetic hyperlipidemia. FHCL is associated with high prevalence of cardiovascular disease. In this study we selected 208 patients affected by FHCL and evaluated the efficacy of the lipid-lowering statin therapy using different statins available in the market. The results show that the percent of patients reaching the therapeutic goal ranges from 19.7 % (LDL-C <100 mg/dL) to 50.9% (LDL-C <130 mg/dL) and from 16.9 % (non HDL-C <130 mg/dL) to 46.6 % (non HDL-C <160 mg/dL) according to the different ATPIII-NCEP-guidelines cut offs. In conclusion the statin monotherapy is only partly effective in the management of FCHL therapy

statin familial combined hyperlipidemia therapy
researchProduct

Plasma non-cholesterol sterols: a useful diagnostic tool in pediatric hypercholesterolemia.

2010

Current guidelines strongly recommend the identification of genetic forms of hypercholesterolemia (HC) during childhood. The usefulness of non–cholesterol sterols (NCS) in the diagnosis of genetic HC has not been fully explored. Plasma NCS were measured by gas chromatography/mass spectrometry (GC/MS) in 113 children with hypercholesterolemia affected by: autosomal dominant hypercholesterolemia (ADH), familial combined hyperlipidemia (FCHL), polygenic hypercholesterolemia (PHC), and in 79 controls to evaluate: i) plasma NCS profile in different genetic HC and ii) the usefulness of NCS for the diagnosis of HC beyond current clinical criteria. ADH was characterized by raised lathosterol/total …

Cholesterol synthesisMalemedicine.medical_specialtyMultifactorial InheritanceSettore MED/09 - Medicina InternaAdolescentHyperlipidemia Familial CombinedLathosterolIncreased Cholesterol Synthesisbehavioral disciplines and activitiesGas Chromatography-Mass SpectrometryHyperlipoproteinemia Type IIchemistry.chemical_compoundPredictive Value of TestsInternal medicineBlood plasmaMedicineHumansGenetic Predisposition to DiseaseChildhypercholesterolemiabusiness.industryCholesterolDiscriminant AnalysisPhytosterolsSitosterolsSterolFamilial combined hyperlipidemiaSterolsEndocrinologypediatricCholesterolchemistryItalyCase-Control StudiesPediatrics Perinatology and Child Healthlipids (amino acids peptides and proteins)FemalebusinessBiomarkersLipoproteinPediatric research
researchProduct

Insulin resistance and oxidative stress in familial combined hyperlipidemia.

2007

Oxidative stress is associated with atherosclerosis. Familial combined hyperlipidemia (FCH) is considered as a human model of primary dyslipidemia and atherosclerosis frequently associated with insulin resistance (IR), but there are few data on its possible relation to oxidative stress. The objective of this study was to evaluate oxidative stress status using different markers in subjects with FCH assessing its possible correlation with anthropometric parameters and IR. This was a cross-sectional study. A cohort of 40 FCH patients (20 with IR (HOMAor=3.2) and 20 without IR (HOMA3.2)), and 20 healthy volunteers were included, all of them non-diabetic, normotensive and non-smokers. We measure…

AdultMalemedicine.medical_specialtyAdolescentHyperlipidemia Familial Combinedmedicine.disease_causeAnthropometric parametersInsulin resistanceInternal medicinemedicineHumansAgedGlutathione Disulfidebusiness.industryVascular diseasenutritional and metabolic diseasesDeoxyguanosineMiddle Agedmedicine.diseaseAtherosclerosisGlutathioneLipidsFamilial combined hyperlipidemiaOxidative StressEndocrinology8-Hydroxy-2'-DeoxyguanosineCohortFemaleInsulin ResistanceCardiology and Cardiovascular MedicinebusinessDyslipidemiaOxidative stressAtherosclerosis
researchProduct

Arteriosclerosis carotídea subclínica en pacientes con hiperlipidemia familiar combinada. Evolución tras dos años de tratamiento con dosis altas de a…

2012

Resumen Fundamento y objetivo La hiperlipidemia familiar combinada (HFC) es un modelo genetico de dislipidemia aterogenica con insulinorresistencia y cardiopatia isquemica precoz. Nuestro objetivo fue evaluar la presencia de alteraciones a nivel carotideo, como marcador de arteriosclerosis sistemica, en sujetos con HFC, y valorar el efecto del tratamiento con 80 mg de atorvastatina diarios durante 2 anos sobre el grosor de la placa de ateroma. Sujetos y metodos Estudiamos 100 sujetos con HFC sin diabetes en prevencion primaria reclutados consecutivamente. Se determinaron parametros clinicos y bioquimicos, y se realizo ecografia carotidea. En los sujetos con placa de ateroma se inicio tratam…

GynecologyFamilial combined hyperlipidemiamedicine.medical_specialtyTratamiento farmacologicoPrevencion primariabusiness.industryCarotid arteriesMedicineGeneral MedicineUltrasonographybusinessMedicina Clínica
researchProduct